Novavax, Inc (NASDAQ:NVAX) has a beta value of 3.22 and has seen 1.01 million shares traded in the recent trading session. The company, currently valued at $974.72M, closed the recent trade at $6.06 per share which meant it gained $0.06 on the day or 1.00% during that session. The NVAX stock price is -293.73% off its 52-week high price of $23.86 and 37.13% above the 52-week low of $3.81. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.12 million shares traded. The 3-month trading volume is 4.31 million shares.
The consensus among analysts is that Novavax, Inc (NVAX) is Buy stock at the moment, with a recommendation rating of 2.14. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 16 have rated it as a Hold, with 10 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.42.
Novavax, Inc (NASDAQ:NVAX) trade information
Sporting 1.00% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the NVAX stock price touched $6.06 or saw a rise of 18.33%. Year-to-date, Novavax, Inc shares have moved -24.63%, while the 5-day performance has seen it change -18.00%. Over the past 30 days, the shares of Novavax, Inc (NASDAQ:NVAX) have changed -21.09%. Short interest in the company has seen 37.55 million shares shorted with days to cover at 7.71.
Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 72.45% from the levels at last check today. The projected low price target is $14.0 while the price target rests at a high of $25.0. In that case, then, we find that the latest price level in today’s session is -312.54% off the targeted high while a plunge would see the stock gain -131.02% from the levels at last check today.
Novavax, Inc (NVAX) estimates and forecasts
The company’s shares have lost -52.02% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -26.12%.
4 analysts offering their estimates for the company have set an average revenue estimate of 67.7M for the current quarter. 4 have an estimated revenue figure of 150.3M for the next ending quarter. Year-ago sales stood 93.86M and 415.48M respectively for this quarter and the next, and analysts expect sales will shrink by -27.87% for the current quarter and -26.12% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 25.88% over the past 5 years. Earnings growth for 2025 is a modest 81.77% while over the next 5 years, the company’s earnings are expected to increase by 67.92%.
NVAX Dividends
Novavax, Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Novavax, Inc (NASDAQ:NVAX)’s Major holders
Insiders own 8.80% of the company shares, while shares held by institutions stand at 60.21% with a share float percentage of 66.02%. Investors are also buoyed by the number of investors in a company, with Novavax, Inc having a total of 307.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 14.08 million shares worth more than $178.19 million. As of 2024-06-30, VANGUARD GROUP INC held 10.0599% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 11.85 million shares as of 2024-06-30. The firm’s total holdings are worth over $149.98 million and represent 7.984% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 2.98% shares in the company for having 4.79 shares of worth $28.94 million while later fund manager owns 4.0 shares of worth $24.18 million as of Feb 28, 2025, which makes it owner of about 2.49% of company’s outstanding stock.
